Stocktoria
Terumo Corporation 4543.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Terumo Corporation financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ¥1.13T | ¥1.04T | ¥921.9B | ¥820.2B |
| Gross profit | ¥594.7B | ¥560.7B | ¥479.2B | ¥417.4B |
| SG&A expense | ¥409.9B | ¥381.6B | ¥345.0B | ¥299.9B |
| Operating income | ¥176.3B | ¥157.7B | ¥140.1B | ¥117.3B |
| Interest expense | ¥3.3B | ¥6.2B | ¥2.8B | ¥4.0B |
| Income tax | ¥42.3B | ¥37.6B | ¥34.5B | ¥26.8B |
| Net income | ¥135.9B | ¥117.0B | ¥106.4B | ¥89.3B |
| EPS (diluted) | ¥92.12 | ¥78.99 | ¥71.47 | ¥59.48 |
| Operating cash flow | ¥230.9B | ¥210.8B | ¥146.3B | ¥117.5B |
| Free cash flow | ¥128.9B | ¥128.4B | ¥67.6B | ¥45.4B |
| Cash & equivalents | ¥280.5B | ¥221.9B | ¥204.9B | ¥187.3B |
| Inventory | ¥335.6B | ¥294.4B | ¥286.6B | ¥249.6B |
| Total assets | ¥2.31T | ¥1.83T | ¥1.83T | ¥1.60T |
| Total liabilities | ¥727.7B | ¥459.9B | ¥504.3B | ¥491.2B |
| Shareholders' equity | ¥1.58T | ¥1.37T | ¥1.33T | ¥1.11T |
Growth · year-over-year · Revenue CAGR 11.3%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +9.2% | +12.4% | +12.4% | — |
| Net income growth | +16.2% | +10.0% | +19.1% | — |
| EPS growth | +16.6% | +10.5% | +20.2% | — |
| Free cash flow growth | +0.4% | +90.1% | +48.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · JP · as of 2026-03-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.